A Follow-On Trial to Assess the Long Term Safety and Efficacy of SPM 927 in Painful Distal Diabetic Neuropathy

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

451

Participants

Timeline

Start Date

September 30, 2004

Primary Completion Date

July 31, 2008

Study Completion Date

July 31, 2008

Conditions
Diabetic Neuropathy
Interventions
DRUG

lacosamide

Open-label treatment (two times per day) with film-coated tablets include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, and 600mg/day throughout individual study period.

Trial Locations (84)

Unknown

Anniston

Hoover

Huntsville

Northport

Tuscaloosa

Peoria

Phoenix

Tucson

Hot Springs

Jonesboro

Little Rock

Irvine

Los Angeles

San Diego

Santa Monica

Spring Valley

Tustin

Walnut Creek

Denver

Stratford

Newark

Wilmington

Bradenton

Clearwater

Fort Myers

New Port Richey

Ocala

Pembroke Pines

Pinellas Park

South Miami

St. Petersburg

Sunrise

Tallahassee

Marietta

Chicago

Elk Grove Village

North Chicago

Evansville

West Des Moines

Crestview Hills

Louisville

Madisonville

Paducah

Owings Mills

Towson

Brockton

Ann Arbor

St Louis

Great Falls

Omaha

Las Vegas

Lawrenceville

Voorhees Township

Albany

Mineola

White Plains

Charlotte

Greensboro

Greenville

Raleigh

Winston-Salem

Cincinnati

Toledo

Oklahoma City

Tulsa

Medford

Portland

Upland

Greer

Bristol

Nashville

Amarillo

Dallas

Fort Worth

Houston

Richardson

San Antonio

Bennington

Richmond

Salem

Virginia Beach

Spokane

Tacoma

Wenatchee

Sponsors

Lead Sponsor

All Listed Sponsors
lead

UCB Pharma

INDUSTRY